The role of non-alcoholic fatty liver disease in the formation of atherosclerotic vascular lesions in patients with abdominal obesity

Aim of investigation. To study the vascular wall changes of common carotid artery and internal carotid arteries in patients with abdominal obesity (AO) and different forms of nonalcoholic fatty liver disease (NAFLD). Material and methods. The study involved 60 patients with AO (waist circumference ≥80 cm in women and ≥94 cm in men) and NAFLD who provided written informed consent to participate in the study. The age of the patient ranged from 18 to 59 years. Patients’ symptoms, past history, were evaluated to exclude alcoholic or drug-induced liver disease, anthropometric parameters were studied. All patients underwent a complex of laboratory and instrumental tests required by the Russian guidelines for diagnosis and treatment of NAFLD (2015). Severity of pathological changes in the liver tissue (fibrosis and steatosis) was assessed by noninvasive Steatoskrin diagnostic method (Biopredictive laboratory, France). Measurement of the intima-media complex thickness of the common carotid artery (IMT CCA) was performed by standard procedures at Voluson 730 Expert device, equipped with 7,5 MHz linear phased array transducer. The presence of early atherosclerotic markers was evaluated by local thickening of the IMT CCA over 0.86 mm in any point of the carotid artery (IMT CCA max). The data were processed by comparative and correlation analysis. Results. The relationship between the presence of NAFLD, initial manifestations of atherosclerosis and insulin resistance was established. This resulted in the rank of prognostic factors based on severity of carotid artery changes, making it possible to conclude individual atherosclerotic risk score for AD and different forms of NAFLD. Conclusion. The results of the study require more profound examination of patients with NAFLD to evaluate both liver and cardiovascular diseases risk.

неалкогольная жировая болезнь печени, инсулинорезистентность, атеросклероз

1. Чернецова Е. В., Денисов Н. Л. Окружность талии и индекс массы тела у пациентов с абдоминальным ожирением и различными стадиями фибротических изменений в печеночной ткани при НАЖБП, определяемых с помощью неинвазивных методв диагностики - Стеатоскрина. Рос журн гастроэнтерол гепатол колопроктол 2016; 26 (5, Прил. 48):69.

2. Чернецова Е. В., Денисов Н. Л. Оценка взаимосвязи выраженности изменений в печени - стеатоза, фиброза, с метаболическими параметрами (общего холестерина, триглицеридов) у пациентов с абдоминальным ожирением и с различными формами НАЖБП. Рос журн гастроэнтерол гепатол колопроктол 2016; 26 (5, Прил. 48):69.

3. Чернецова Е. В., Денисов Н. Л. Оценка выраженности фиброза и стеатоза в печеночной ткани у пациентов с абдоминальным ожирением и различными формами НАЖБП. Рос журн гастроэнтерол гепатол колопроктол 2016; 26 (5, Прил. 48):70.

4. Чернецова Е.В, Денисов Н. Л. Изучение зависимости уровней маркёров воспалительно-некротических изменений в печени и прогрессированием стадий НАЖБП у пациентов с абдоминальным ожирением с помощью неинвазивных методов диагностики - Стеатоскрина. Рос журн гастроэнтерол гепатол колопроктол 2016; 26 (5, Прил. 48):69.

5. Мохорт Т. В. Неалкогольная жировая болезнь печени и сахарный диабет: аспекты патогенеза, диагностики и лечения Мед новости 2012; 4:4-10.

6. Пальмер П. Е. Руководство по ультразвуковой диагностике. М.: Медицина, 2000; 5:47-51.

7. Печень и атеросклероз. XXI объединенная российская гастроэнтерологическая неделя. Сателлитный симпозиум компании PROMED. CS Praha. Эффективная фармакотерапия. Гастроэнтерология 2015; 25(4):41-51.

8. Abenavoli L., Milic N., di Renzo L., Preveden T., Medić-Stojanoska M., de Lorenzo A. Metabolic aspects of adult patients with non-alcoholic fatty liver disease. World J Gastroenterol 2016; 22(31):7006-16.

9. Athyros V. G., Tziomalos K., Katsiki N., Doumas M., Karagiannis A., Mikhailidis D. P. Low-fasting triglyceride levels are associated with non-invasive markers of advanced liver fibrosis among adults in the United States. Aliment Pharmacol Ther 2015; 42(1):106-16.

10. Fracanzani A. L., Tiraboschi S., Pisano G., Consonni D., Baragetti A., Bertelli C., Norata D., Valenti L., Grigore L., Porzio M., Catapano A., Fargion S. Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. Atherosclerosis 2016; 246:208-13.

11. Golabi P., Sayiner M., Fazel Y., Koenig A., Henry L., Younossi Z. M. Simple biochemical parameters and a novel score correlate with absence of fibrosis in patients with non-alcoholic fatty liver disease. Indian J Gastroenterol 2015; 34(4):281-5.

12. Grattagliano I., Ubaldi E., Napoli L., Marulli C. F., Nebiacolombo C., Cottone C., Portincasa P. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The «VARES» Italian multicenter study. Ann Hepatol 2013; 12(1):70-7.

13. Ikura Y. Transitions of histopathologic criteria for diagnosis of non-alcoholic fatty liver disease during the last three decades. World J Hepatol 2014; 12(6):894-900.

14. Jacobs K., Brouha S., Bettencourt R., Barrett-Connor E., Sirlin C., Loomba R. Association of non-alcoholic fatty liver disease with visceral adiposity but not coronary artery calcification in the elderly. Clin Gastroenterol Hepatol 2016; 14(9):1337-44.

15. Lee Min-Kyung, Park Hye-Jeong, Jeon Won Seon. Higher association of coronary artery calcification with non-alcoholic fatty liver disease than with abdominal obesity in middle-aged Korean men: the Kangbuk Samsung Health Study. Cardiovasc Diabetol 2015; 14(88):88.

16. Loffroy R., Terriat B., Jooste V., Robin I., Brindisi M. C., Hillon P., Verg s B., Cercueil J. P., Petit J. M. Liver fat content is negatively associated with atherosclerotic carotid plaque in type 2 diabetic patients. Quant Imaging Med Surg 2015; 5(6):792-8.

17. Pais R., Rusu E., Zilisteanu D., Circiumaru A., Micu L., Voiculescu M., Poynard T., Ratziu V. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia. World J Gastroenterol 2014; 40(9):1081-93.

18. Privitera G., Spadaro L., Alagona C., Calanna S., Piro S., Rabuazzo A. M., Purrello F. Hepatic insulin resistance in NAFLD: relationship with markers of atherosclerosis and metabolic syndrome components. Acta Diabetol 2016; 53(3):449-59.

19. Sebastiani G., Alshaalan R., Wong P., Rubino M., Salman A., Metrakos P., Deschenes M., Ghali P. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease. World J Gastroenterol 2015; 21(22):6820-34.

20. Shukla A., Kapileswar S., Gogtay N., Joshi A., Dhore P., Shah C., Abraham P., Bhatia S. Study of FibroTest and hyaluronic acid biological variation in healthy volunteers and comparison of serum hyaluronic acid biological variation between chronic liver diseases of different etiology and fibrotic stage using confidence intervals. Сlinbiochem 2015; 48 (10-11):652.

21. Sinn D. H., Cho S. J., Gwak G. Y., Cho J., Gu S., Seong D., Kang D., Kim H., Yi B. K., Paik S. W. Nonalcoholic fatty liver disease for identification of preclinical carotid atherosclerosis. Medicine (Baltimore) 2016; 95(3):2578.

22. Targher G., Bertolini L., Padovani R. Relations between carotid artery wall thickness and liver histology in subjects with non-alcoholic fatty liver disease. Diabetes Care 2006; 29(6):1325-30.